MINI LONG - VICE PHAR Stock

MINI L VICO AVA

GB00BQRBMS95

Market Closed - Nasdaq Stockholm 09:33:58 2024-05-31 am EDT
11.75 ^SEK	+44.00%

3 months	+261.54%
6 months	+111.71%

Comparison chart between the derivative product and it's underlying value

End-of-day quotes

Chart VICORE PHARMA HOLDING AB

Latest news about VICORE PHARMA HOLDING AB

Increase of number of shares and votes in Vicore Pharma	May. 31	AQ
Transcript : Vicore Pharma Holding AB - Special Call	May. 22
Vicore Announces Positive Final Results from the Phase 2a AIR Trial Demonstrating Buloxibutid Improves Lung Function Over 36 Weeks in Patients with Idiopathic Pulmonary Fibrosis	May. 20	AQ
Vicore Pharma Holding AB Announces Positive Final Results from the Phase 2a Air Trial Demonstrating Buloxibutid Improves Lung Function over 36 Weeks in Patients with Idiopathic Pulmonary Fibrosis	May. 20	CI

More news

Quotes 5-day view

Date	Price	Change
24-05-31	11.75	+44.00%
24-05-29	8.16	+11.17%
24-05-28	7.34	+23.15%

Delayed Quote Nasdaq Stockholm

Last update May 31, 2024 at 09:33 am EDT

More quotes

Static data

Product type	Knock-Out with Stop Loss
Buy / Sell	CALL
Underlying	VICORE PHARMA HOLDING AB
Issuer	Morgan Stanley
	MINI L VICO AVA
ISIN	GB00BQRBMS95
Date issued	2023-03-02
Strike	9.908 kr
Maturity	Unlimited
Parity	1 : 1
Emission price	- kr
Emission volume	N/A
Settlement	cash
Currency	SEK

Technical Indicators

Highest since issue	16.03 kr
Lowest since issue	3.25 kr
Spread	-0.83 kr
Spread %	8.30%

Company Profile

Vicore Pharma Holding AB is a Sweden-based drug-development company. The Company's portfolio contains small molecules with potential indications, including anti-inflammation, nerve generation and cardiovascular disease. The Company is a wholly owned subsidiary of Mintage Scientific AB.

Sector

More about the company

Consensus: Vicore Pharma Holding AB

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

22 SEK

Average target price

61.5 SEK

Spread / Average Target

+179.55%

Consensus